An Taoiseach Leo Varadkar, Prime Minister of Ireland announced that WuXi Biologics, a Hong Kong global open-access biologics technology platform company, is to invest €325 million and create 400 new jobs over five years in a new biologics drug substance manufacturing facility on the Industrial Development Authority’s (IDA) greenfield site in Mullagharlin, Dundalk, Ireland.
This state-of-the-art “facility of the future” will be built upon the novel approach WuXi Biologics has pioneered deploying multiple single-use bioreactors for commercial biomanufacturing and is also designed to be able to run continuous bioprocessing, a next generation manufacturing technology to be first implemented globally in this campus. A total of 48,000 L fed-batch and 6,000 L perfusion bioreactor capacity will be installed, representing the world’s largest facility using single-use bioreactors.
The manufacturing project in a 26-hectare campus, the company’s first site outside of China, is supported by the Irish Government through IDA Ireland.
Dr. Chris Chen, CEO of WuXi Biologics, commented: “We are all excited to initiate our first global site to enable local companies and expedite biologics development in Europe. In addition, this is the start and a critical part of our global biomanufacturing network to ensure that biologics are manufactured at the highest quality and with a robust supply chain to benefit patients worldwide. We are committed to Ireland and will work with all local partners to build this state-of-art next generation biomanufacturing facility as a showcase to the global biotech community.”